Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Reexamination Certificate
2004-10-12
2010-12-14
Dunston, Jennifer (Department: 1636)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
C514S002600, C514S021800, C514S04400A, C435S455000
Reexamination Certificate
active
07850959
ABSTRACT:
The present invention features methods and compositions for preventing, reducing, or treating hypoxia and pathological disorders involving abnormal angiogenesis (e.g., conditions involving decreases or increases in blood flow, respectively). Where an increase in angiogenesis is desired, the mammal being treated for an ischemic condition is provided with Related Transcriptional Enhancer Factor-1 (RTEF-1; as a recombinant polypeptide or as an expression vector) sufficient to increase expression of VEGF, FGFR, or COX-2. This results in a concomitant increase in angiogenesis. Conversely, a mammal being treated for a hypervascular condition is administered a composition that reduces the levels of RTEF-1, thereby reducing the expression of VEGF, FGFR, or COX-2, which results in a decrease in angiogenesis. Also disclosed are screening methods that make use of RTEF-1 for the identification of novel therapeutics for the treatment, prevention, or reduction of pathological disorders involving hypoxia or abnormal angiogenesis, namely, ischemic or hypervascular conditions.
REFERENCES:
patent: 2002/0142457 (2002-10-01), Umezawa et al.
Stewart et al. Cloning of Human RTEF-1, a Transcriptional Enhancer Factor-1-Related Gene Preferentially Expressed in Skeletal Muscle: Evidence for an Ancient Multigene Family. Genomics, vol. 36, pp. 68-76, 1996.
Ueyama et al. Identification of the functional domain in the transcription factor RTEF-1 that mediates alpha 1-adrenergic signaling in hypertrophied cardiac myocytes. Journal of Biological Chemistry, vol. 275, pp. 17476-17480, 2000.
Burglin, TR. The TEA domain: a novel, highly conserved DNA-binding motif. Cell, vol. 66, pp. 11-12, Jul. 1991.
Gupta et al. Human studies of angiogenic gene therapy. Circulation Research, vol. 105, No. 8, pp. 724-736, Oct. 2009.
Strayer, DS. Gene therapy using SV40-derived vectors: what does the future hold? Journal of Cellular Physiology, vol. 181, pp. 375-384, 1999.
Ehrhardt et al. Episomal vectors for gene therapy. Current Gene Therapy, vol. 8, pp. 147-161, 2008.
Strayer et al. What can SV40-derived vectors do for gene therapy? Current Opinion in Molecular Therapeutics, vol. 4, No. 4, pp. 313-323, Aug. 2002.
Hewson. RNA viruses: emerging vectors for vaccination and gene therapy. Molecular Medicine Today, vol. 6, pp. 28-35, Jan. 2000.
Entry for TEAD 4 TEA domain family member 4 [Homo sapiens], GeneID: 7004, printed from Entrez Gene (www.ncbi.nlm.nih.gov) on Oct. 23, 2009 as pp. 1/7 to 7/7.
GenBank Accession No. NP—003204, GI: 4507427, publicly available Oct. 2000, printed as pp. 1-2.
Laham Roger J.
Li Jian
Shie Jue-Lon
Armstrong Todd
Beth Israel Deaconess Medical Center
Bieker-Brady Kristina
Clark & Elbing LLP
Dunston Jennifer
LandOfFree
Methods and compositions for treating conditions involving... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for treating conditions involving..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for treating conditions involving... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4212379